



## **London 2019, Panel Session**

### **Patent linkage an international perspective**

The panel session will address patent linkage, *i.e.* the possible connection between the market approval process for generic or biosimilar drugs and the patent status of the reference drug. Countries like the USA have long implemented patent linkage systems for generic drugs and biosimilars. Patent linkage is now also starting to emerge as a regional methodology in Asia, including China, as such a system is seen to provide some clarity to market players through the early resolution of patent issues. A large variety of patent linkage systems exists.

In contrast, the European Union has not adopted a patent linkage system, although in European countries, some information is provided to the patent holder at some stages of marketing authorisation and price setting.

This panel session will examine the patent linkage systems of several countries and update attendees on the current situation globally. The session will include discussion between the speakers regarding the advantages and disadvantages of patent linkage, and other ways of solving the problems addressed by patent linkage. This panel session will consist of speakers from Europe, USA and Latin America.